

Anaesthesia recommendations for patients suffering from

Glutaric acidemia type 1

Disease name: Glutaric acidemia type 1

ICD 10: E72.3 - Disorders of lysine and hydroxylysine metabolism

Synonyms: Glutaric aciduria type 1

Glutaric acidemia type 1 (GA1) is a rare hereditary metabolic disorder with an autosomal recessive mode of inheritance. GA1 has an estimated overall prevalence of 1 in 100,000 newborns and is caused by a deficiency of glutaryl-CoA dehydrogenase, a mitochondrial enzyme involved in the metabolism of lysine, hydroxylysine and tryptophan.

Untreated, approximately 90% of patients will develop neurological disease during a finite period of brain development (age 3-36 months) following an acute encephalopathic crisis often precipitated by gastroenteritis, intercurrent febrile illness, immunization or surgical intervention. GA1 can also develop insidiously without clinically apparent crisis in 10 to 20% of the patients.



Medicine in progress

Perhaps new knowledge

Every patient is unique

Perhaps the diagnostic is wrong



Find more information on the disease, its centres of reference and patient organisations on Orphanet: www.orpha.net

Disease summary

Presenting symptoms include macrocephaly at birth or shortly thereafter, psychomotor delay, dystonia and, later, spastic quadriparesis. Patients seem to have relatively normal cognition, respond to commands, but have trouble talking or performing tasks because of poor muscle coordination and severe spasticity. Also mild cases causing only slight neurological complaints and/or fatigue have been described.

Brain imaging performed shortly after birth usually shows frontoparietal atrophy with widening of Sylvian fissures and arachnoid cysts. The brain is more vulnerable to head trauma that can lead to acute subdural or retinal haemorrhage.

The cerebral damage seen in GA1 is caused by the direct effect of glutaric acid or a related metabolite. Glutaric acid, 3-hydroxyglutaric acid, and glutaconic acid accumulate in the brain and lead to neuronal damage, lymphocyte infiltration, elevated concentrations of inflammatory cytokines and nitric oxide, glial proliferation, atrophy of striatal neurons and neurologic dysfunction.

Typical surgery

Neurosurgery (cerebral spinal fluid shunting procedures for hydrocephalus and subdural fluid collections); muscle biopsy, general surgery; neuroradiological imaging procedures.

Type of anaesthesia

No definite recommendation for either general or regional anaesthesia can be done.

Patient compliance and collaboration for regional anaesthesia may be difficult due to dystonia. No reports about spinal, epidural and caudal anaesthesia.

For general anaesthesia, there are no definite reports on the superiority of one anaesthetic drug over another.

No contraindication for sedation or analgesia. Consider risk of aspiration.

Necessary additional diagnostic procedures (preoperative)

If surgical intervention is planned, the responsible metabolic center/specialist should be informed beforehand. This would enable all staff involved to discuss specific risks and to have a protocol for perioperative metabolic management and monitoring.

No need for additional specific preoperative tests. Routine preoperative tests are usually normal.

Some patients have chronically reduced bicarbonate levels while perfectly compensated. During acute attacks one can expect hypoglycaemia, ketonuria and metabolic acidosis with mild to moderate decrease of bicarbonate levels.

Particular preparation for airway management

Patients with severe dystonia may be at a greater risk for aspiration of gastric contents during general anaesthesia. Appropriate measures to avoid aspiration including use of proton-pump inhibitors/H2-blockers and rapid sequence anaesthesia induction should be considered.

At the end of the surgical procedure, tracheal extubation must be carried out when the patient is awake and when protective reflexes become present.

Particular preparation for transfusion or administration of blood products

Not reported.

Particular preparation for anticoagulation

Not reported.

Particular precautions for positioning, transport or mobilisation

Not reported.

Probable interaction between anaesthetic agents and patient's long-term medication

Not reported.

Patients are usually treated on low protein (lysine and tryptophan restriction) diet, riboflavin and carnitine supplementation. Carnitine dosage should be doubled during the perioperative period.

Anaesthesiologic procedure

Regarding volatile anaesthetics, sevoflurane seems to be safe. Recent literature rules out episodes of malignant hyperthermia and other intraoperative events attributable to the general anaesthesia with sevoflurane in paediatric patients with mitochondrial disease.

Reports that propofol can provide lipid overload and inhibit oxidative phosphorylation, carnitine palmitoyltransferase transport of long-chain fatty acids, and β -oxidation of fatty acid in mitochondria raises concerns about the possibility of occurrence of propofol infusion syndrome and severe metabolic acidosis. Long procedures with total intravenous anaesthesia with propofol are probably not advisable. There are reports of use of thiopentone for induction without complications.

Expect prolonged responses to non-depolarizing muscle relaxants and hyperkalemic responses to succinylcholine. Antagonisation of neuromuscular blockade with pyridostigmine or neostigmine seems to be possible. Sugammadex to antagonize any residual neuromuscular blockade is maybe a good option.

Limit the preoperative fasting period to prevent hypoglycaemia, dehydration and mild metabolic acidosis caused by an overnight fast. Start a maintenance intravenous infusion containing glucose 6 mg/kg/min during fasting period.

Intraoperative avoid using Ringer's lactate since it contains lactic acid, and used dextrose in normal saline instead.

Patients with GA-1 are vulnerable to postoperative emesis. Antiemetic prophylaxis is advisable.

Particular or additional monitoring

Monitoring of the neuromuscular blockade is strictly recommended if any neuromuscular blocking agent is used.

Monitor body temperature to avoid hypothermia, shivering and increased oxygen demand.

Consider serial intraoperative arterial blood gas analysis for closely monitor pH status, electrolytes, lactate levels and glucose level.

Possible complications

Possible encephalopathic crisis and acute metabolic decompensation may occur during surgery and the postsurgical period, especially during ages 0 to 6 years. With increasing age, in particular after age 6 years, the risk of acute neurological insult appears to be much reduced.

Conditions accelerating catabolism, such as repeated vomiting and diarrhoea (with or without fever), and the manifestation of severe neurological symptoms (i.e., hypotonia, irritability, rigor, dystonia, reduced consciousness) should be considered as alarming symptoms.

Emergency treatment should aim to start before the onset of alarming neurological symptoms:

- (1) Prevention or reversal of a catabolic state by administration of a high energy intake (plus insulin to control for hyperglycaemia if required);
- (2) Reduction of glutaric acid or related metabolite production by transient reduction or omission of natural protein for 24 to 48 hours;
- (3) Amplification of physiological detoxification mechanisms and prevention of secondary carnitine depletion by L-carnitine supplementation;
- (4) Maintenance of normal fluid, electrolytes and pH status via enteral or IV fluids.

Non-adherence to previously described emergency treatment recommendations has been associated with a high probability of developing striatal injury.

Postoperative care

If possible, the post surgical metabolic management should be performed in a metabolic centre.

Consider emergency treatment described above.

Information about emergency-like situations / Differential diagnostics

Repeated vomiting and diarrhoea (with or without fever), and the manifestation of severe neurological symptoms (i.e., hypotonia, irritability, rigor, dystonia, reduced consciousness) should be considered as alarming symptoms in post-operative period and may indicate an acute metabolic decompensation.

Ambulatory anaesthesia

Two cases reported (patients aged 12 and 16 years old) for ambulatory neuroradiological imaging, for routine follow up.

Sedation was performed with a propofol bolus 1mg/kg and maintained using propofol bolus 0.5mg/Kg in case of necessity, during approximately 10 minutes. Spontaneous breathing was maintained during this time period, without any complications reported.

Ambulatory anaesthesia should probably consider only for older patients (more than 6 years) and only for low risk procedures and surgery.

Obstetrical anaesthesia

During the last three decades therapeutic concepts have been established, which permitted to optimize and reduce the frequency of acute encephalopathic crises and thus morbidity and mortality in early diagnosed patients with GA1.

Therefore, GA1 is now considered to be a treatable condition. However, to the best of our knowledge, until present date, there are no reports about pregnancy and/or obstetrical anaesthesia in GA1 patients.

Literature and internet links

1. Stefan K, et al. Diagnosis and management of glutaric aciduria type I – revised recommendations; *J Inherit Metab Dis* 2011;34:677-694; DOI:10.1007/s10545-011-9289-5
2. Hernández-Palazón J, et al. Anesthetic management in two siblings with glutaric aciduria type 1; *Paediatr Anaesth* 2006;16:188-191; DOI:10.1111/j.1460-9592.2005.01629
3. Teng WN, et al. Anesthetic management of comprehensive dental restoration in a child with glutaric aciduria type 1 using volatile sevoflurane; *J Chin Med Assoc* 2014;548-551; DOI:10.1016/j.jcma.2014.06.010
4. Tsiotou AG, et al. The child with glutaric aciduria type I: anesthetic and perioperative management; *J Anesth* 2011;25:301-304; DOI:10.1007/s00540-010-1083-2
5. Fudickar A, Bein B. Propofol infusion syndrome: update of clinical manifestation and pathophysiology, *Minerva Anesthesiol* 2009;75:399-344; PMID:19412155
6. Funk CB, et al. Neuropathological, biochemical and molecular findings in a glutaric academia type 1 cohort; *Brain* 2005;128:711-722; DOI:10.1093/brain/awh401
7. Kölker S, et al. Natural history, outcome, and treatment efficacy in children and adults with glutaryl-CoA dehydrogenase deficiency; *Pediatr Res* 2006;59:840-847; DOI: 10.1203/01.pdr.0000219387.79887.86
8. Footitt EJ, et al. Mitochondrial disorders and general anaesthesia: a case series and review; *Br J Anaesth* 2008;100:436-441; DOI:10.1093/bja/aen014
9. Goktas U, et al. Management of outpatient anesthesia in an unusually case with glutaric aciduria type-1; *Pediatr Anesth* 2009;19:623-633; DOI:10.1111/j.1460-9592.2009.02893.x.

Last date of modification: October 2016

This guideline has been prepared by:

Author

Patricia Martins, Anaesthesiologist, Centro Hospitalar Lisboa Norte, Lisbon, Portugal
psmartins89@gmail.com

Peer revision 1

Chun-Sung Sung, Anaesthesiologist, Taipei Veterans General Hospital, Taipei,
Taiwan, Republic of China
cssung@vghtpe.gov.tw

Peer revision 2

Mirian Janssen, Departments of Internal Medicine, Radboud University Medical Centre,
Nijmegen, The Netherlands
Mirian.Janssen@radboudumc.nl
